KRAS and acute myeloid leukemia: However, the antileukemic activity of trametinib appeared heterogeneous in primary samples from AML patients when assayed ex vivo in colony formation assays, with a significantly lower efficacy against KRAS- or PTPN11-mutated compared to NRAS or non-RAS−mutated samples, as reported [6].